• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Enovis Corporation

    6/26/25 4:45:47 PM ET
    $ENOV
    Industrial Specialties
    Health Care
    Get the next $ENOV alert in real time by email
    11-K 1 enovis401ksavingsplan20241.htm 11-K Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    FORM 11-K


     
    xANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the fiscal year ended December 31, 2024
    OR
     
    ¨TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
    For the transition period from                     to                     

    Commission file number - 001-34045


     
    A.    Full title of the plan and the address of the plan, if different from that of the issuer named below:
    Enovis 401(k) Savings Plan Plus
    B.     Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

    Enovis Corporation
    2711 Centerville Road, Suite 400
    Wilmington, DE 19808




    TABLE OF CONTENTS


     Page
    Report of Independent Registered Public Accounting Firm
    1
    Financial Statements
    Statements of Net Assets Available for Benefits
    2
    Statement of Changes in Net Assets Available for Benefits
    3
    Notes to Financial Statements
    4
    Supplemental Schedule
    Schedule H, Line 4i - Schedule of Assets (Held at End of Year)
    9
    Signatures
    10
    Exhibits
    11





    Report of Independent Registered Public Accounting Firm

    Plan Administrator and Participants
    Enovis 401(k) Savings Plan Plus
    Wilmington, Delaware

    Opinion on the Financial Statements

    We have audited the accompanying statements of net assets available for benefits of the Enovis 401(k) Savings Plan Plus (the “Plan”) as of December 31, 2024 and 2023, the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively, the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2024 and 2023, and the changes in net assets available for benefits for the year ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

    Basis for Opinion

    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

    Our audits included performing procedures to assess the risk of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by the Plan’s management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

    Supplemental Information

    The supplemental information in the accompanying schedule H, Line 4i- Schedule of Assets (Held at End of Year) as of December 31, 2024 has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is presented for the purpose of additional analysis and is not a required part of the financial statements but included supplemental information required by the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ BDO USA, P.C.

    We have served as the Plan’s auditor since 2014.

    Miami, Florida
    June 26, 2025
    1

    ENOVIS 401(k) SAVINGS PLAN PLUS
    STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS


    December 31,
    20242023
    Assets
    Investments, at fair value$289,205,661 $258,254,158 
    Receivables:
    Employer contributions453,086 349,357 
    Notes receivable from participants2,789,070 2,737,950 
    Total receivables3,242,156 3,087,307 
    Net assets available for benefits$292,447,817 $261,341,465 

    See Notes to Financial Statements.

    2

    ENOVIS 401(k) SAVINGS PLAN PLUS
    STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS

    Year Ended December 31, 2024
    Additions to net assets attributed to:
    Contributions:
    Participant$15,854,940 
    Employer8,874,424 
    Rollovers4,946,950 
    Total contributions29,676,314 
    Net investment income:
    Dividends and interest3,617,020 
    Net appreciation in fair value of investments35,852,665 
    Total net investment income39,469,685 
    Interest income from notes receivable from participants220,062 
    Total additions69,366,061 
    Deductions from net assets attributed to:
    Benefits paid to participants37,875,894 
    Administrative expenses, net383,815 
    Total deductions38,259,709 
    Net increase31,106,352 
    Net assets available for benefits:
    Beginning of plan year261,341,465 
    End of plan year$292,447,817 

    See Notes to Financial Statements.

    3

    ENOVIS 401(k) SAVINGS PLAN PLUS
    NOTES TO FINANCIAL STATEMENTS

    1. Description of the Plan

    The following description of the Enovis 401(k) Savings Plan Plus (the “Plan”) provides only general information. Participants should refer to the Plan document for a complete description of the Plan's provisions.

    General

    The Plan, as amended and restated as of January 1, 2020 (the “2020 Plan Amendment”), is a defined contribution plan covering substantially all employees of Enovis Corporation and participating affiliates (collectively, “Enovis,” the “Company,” or the “Employer”). Non-resident aliens, leased employees, temporary employees who are not 21 years of age and have not completed at least 1,000 hours of service during an eligibility period, and employees not on payroll in the United States of America are not included in the Plan. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (“ERISA”). The plan is administered by Enovis Corporation (the “Plan Administrator”).

    Contributions

    Each year, participants may contribute up to 75% of pretax annual compensation, as defined in the Plan. Participants are automatically enrolled with a 4% deferral contribution upon attainment of the eligibility requirements unless the Company receives signed written documentation from the participant before this date to do otherwise. Participants who have attained age 50 before the end of the Plan year are eligible to make catch-up contributions. The Plan provides for a safe harbor employer match of up to 4% of eligible compensation contributed to the Plan and discretionary employer contribution of eligible compensation for the year ended December 31, 2024, based upon eligibility requirements as detailed in the Plan document. Participants may also contribute amounts representing eligible rollover distributions from other qualified plans. Contributions are subject to certain limitations.

    Participant Accounts

    Each participant's account is credited with the participant's contributions, the Company's contributions, and an allocation of the investment earnings and losses. On a quarterly basis, participant accounts are charged with a set fee for administrative expenses that are paid by the Plan. Participant initiated transactions are paid directly through participant accounts. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account. Participants direct the investment of contributions into various investment options offered by the Plan. As of December 31, 2024, the Plan offered 13 mutual funds, 13 common collective trust funds, and Enovis common stock as investment options for participants. Effective April 5, 2022, following the Company’s name change and separation of its fabrication technology business, ESAB, Colfax common stock began trading as Enovis common stock and a portion of the common stock in the Plan was converted to ESAB common stock, a new publicly traded stock. However, ESAB common stock is not an investment option available to be purchased through the Plan.

    Vesting

    Participants vest immediately in their contributions, safe harbor employer contributions, and discretionary employer contributions; plus actual earnings (losses) thereon. Prior to the 2020 Plan Amendment, vesting in discretionary employer contributions was based on years of continuous service as follows: 20% vested after two years of services, 40% vested after three years, 60% vested after four years, and 100% vested after five years of service. Different vesting schedules may apply to certain employees as described in the Plan document due to prior Plan provisions.

    Forfeited Accounts

    As of December 31, 2024 and 2023, forfeited nonvested accounts totaled $88,125 and $27,047, respectively. On a periodic basis at the discretion of plan management, the Company may use the forfeited nonvested accounts to reduce future employer contributions or pay administrative expenses. During the year ended December 31, 2024, no forfeited nonvested funds were used to reduce Employer contributions or pay administrative expenses.

    4

    ENOVIS 401(k) SAVINGS PLAN PLUS
    NOTES TO FINANCIAL STATEMENTS – (Continued)

    Payment of Benefits

    Benefits are payable upon retirement at age 65, disability, death, or termination of employment. Hardship withdrawals and in-service withdrawals at age 59 1/2 are also permitted, subject to the provisions in the Plan document and applicable law. Benefits are payable in lump sum or installment payments.

    Notes Receivable from Participants

    Active participants may borrow from their fund accounts a minimum of $1,000 up to a maximum of the lesser of $50,000 or 50% of their vested account balance. For loans to active participants in the Plan, loan terms range from one to five years or up to 15 years for the purchase of a primary residence. Notes receivable from participants are repaid through payroll deductions. The loans are secured by the balance in the participant's account and bear interest at the prime rate plus 1%.

    Administrative Expenses

    Certain expenses of administering the Plan are paid by the Plan through a flat fee pricing arrangement with the recordkeeper and Trustee, Bank of America, N.A. Under this arrangement, each participant is charged a set quarterly fee to cover certain costs of administrating the Plan. Administrative expenses also include member-requested services charged to participant accounts. Investment related expenses are included in Net appreciation in fair value of investments in the Statement of Changes in Net Assets Available for Benefits. Other professional fees paid by the Plan are discussed further in Note 6, “Related Party and Party-In-Interest Transactions”. Certain other administrative expenses associated with maintaining the Plan may be paid by the Company and are excluded from the financial statements.

    Voting Rights
        
    Each participant is entitled to exercise voting rights for shares of Enovis and ESAB common stock credited to their account at all times as their respective company’s shareholders vote. The participant is notified by the Trustee prior to the time such rights are to be exercised. The Trustee is not permitted to vote any allocated share for which instructions have not been given by a participant. The Trustee shall vote shares for which it has not received direction in the same proportion as directed shares were voted.


    2. Significant Accounting Policies

    Basis of Accounting

    The financial statements of the Plan are prepared on the accrual basis of accounting, in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

    Investment Valuation and Income Recognition

    The investments of the Plan are stated at fair value. The Plan performs fair value measurements in accordance with FASB Accounting Standards Codification 820, Fair Value Measurement (“ASC 820”). The Retirement Plan Advisory Committee determines the Plan’s valuation policies, utilizing information provided by the investment advisors and Trustee. See Note 3, “Fair Value Measurements” for further discussion of investment valuation inputs.

    Purchases and sales of investments are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Net appreciation in fair value of investments includes the Plan’s gains and losses on investments bought and sold as well as held during the year. Dividends are recorded on the ex-dividend date.

    Notes Receivable from Participants

    The notes receivable from participants are measured at their unpaid principal balance plus any accrued but unpaid interest. Delinquent participant loans are reclassified as distributions based upon the terms of the Plan document. During the year ended December 31, 2024 there were no deemed distributions from the Plan. Principal and interest are paid through payroll deductions.

    5

    ENOVIS 401(k) SAVINGS PLAN PLUS
    NOTES TO FINANCIAL STATEMENTS – (Continued)

    Contribution Receivable

    Participant contributions and any related employer matching contributions are recognized in the period during which the Company makes the respective payroll deduction from the participant’s compensation. Non-elective and profit sharing contributions are recorded in the relevant period in accordance with the terms in the plan.

    Payment of Benefits

    Benefits are recorded when paid.

    Use of Estimates

    The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the additions and deductions to net assets available for benefits for the periods presented. Actual results may differ from those estimates.


    3. Fair Value Measurements

    The Plan performs fair value measurements of financial instruments defining fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Plan reports its investments at fair value based on a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level One) and the lowest priority to unobservable inputs (Level Three). The three levels of the fair value hierarchy are described below:

    Level One: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets.

    Level Two: Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

    Level Three: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.
    A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.

    A summary of the Plan's assets that are measured at fair value for each fair value hierarchy level for the periods presented is as follows:
    December 31, 2024
    Measured at Net Asset Value (1)
    Level
    One
    Level
    Two
    Level
    Three
    Total
    Enovis Corporation common stock$— $481,990 $— $— $481,990 
    ESAB Corporation common stock— 368,044 — — 368,044 
    Mutual funds— 136,481,145 — — 136,481,145 
    Common collective trust fund151,874,482 — — — 151,874,482 
    Total$151,874,482 $137,331,179 $— $— $289,205,661 
    6

    ENOVIS 401(k) SAVINGS PLAN PLUS
    NOTES TO FINANCIAL STATEMENTS – (Continued)

    December 31, 2023
    Measured at Net Asset Value (1)
    Level
    One
    Level
    Two
    Level
    Three
    Total
    Enovis Corporation common stock$— $524,950 $— $— $524,950 
    ESAB Corporation common stock— 338,481 — — 338,481 
    Mutual funds— 244,029,168 — — 244,029,168 
    Common collective trust fund13,361,559 — — — 13,361,559 
    Total$13,361,559 $244,892,599 $— $— $258,254,158 
    __________
    (1) In accordance with ASC 820, certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient (the “NAV”) have not been classified in the fair value hierarchy. These investments, consisting of common collective trusts, are valued using the NAV provided by the Trustee. The NAV is based on the underlying investments held by the fund that are traded in an active market, less its liabilities. These investments can be redeemed in the near term.

    The fair value of the investments of the Plan were determined as follows:

    Enovis Corporation common stock and ESAB Corporation common stock are valued at the closing price reported on a national securities exchange.

    Mutual funds are valued at the daily closing prices as reported by the fund. Mutual funds held by the Plan are open ended mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily net asset value and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

    The investments in the common collective trust funds, including the Morley Stable Value Fund and the Vanguard Target Retirement Funds, can be redeemed immediately at the current NAV. The NAV as reported by the Trustees are used as a practical expedient to estimate fair value, which is based on the fair value of the underlying assets in the trusts, less its liabilities. The investments are direct filing entities. There are no withdrawal limits, redemption frequency limits or redemption notice periods. There were no unfunded commitments for these investments as of December 31, 2024 or 2023.

    Withdrawals for benefit payments and participant directed transfers to noncompeting options are made to plan participants promptly, to the extent possible, but within 30 days after notification has been received. The Morley Stable Value Fund reserves the right to delay plan sponsor-initiated redemptions for up to 365 days, subject to certain conditions.


    4. Risks and Uncertainties

    The Plan provides for investments in various securities that are exposed to risks, such as interest rate, credit and overall volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect the amounts reported in future Statements of Net Assets Available for Benefits.


    5. Tax Status

    Effective October 3, 2022, the Plan Sponsor adopted the Pre-Approved Defined Contribution Plan sponsored by Bank of America Merrill Lynch, (the “Pre-Approved Plan”). The Pre-Approved Plan received an opinion letter dated June 30, 2020 in which the Internal Revenue Service (“IRS”) stated that the Pre-Approved Plan was in compliance with the applicable requirements of the Internal Revenue Code (“Code”). In addition, the opinion letter stated that an employer who adopts this Pre-Approved Plan may rely on the opinion letter with respect to the qualification under the Code. Therefore, Plan management believes that the Plan is designed and being operated in compliance with the applicable provisions of the Code.

    GAAP requires Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the Plan has taken an uncertain position that more-likely-than-not would not be sustained upon examination by the IRS. Plan management has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2024, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial
    7

    ENOVIS 401(k) SAVINGS PLAN PLUS
    NOTES TO FINANCIAL STATEMENTS – (Continued)

    statements. The Plan is subject to routine audits by taxing jurisdictions, however, there are currently no audits for any tax periods in progress.


    6. Related Party and Party-in-Interest Transactions

    Plan investments include the Company’s common stock. Enovis Corporation is the administrator of the Plan. For the year ended December 31, 2024, transactions involving the Company's common stock included sales of approximately $122,911 and purchases of approximately $210,704. For the year ended December 31, 2023, transactions involving the Company's common stock included sales of approximately $105,513 and purchases of approximately $278,347. There was no dividend income with respect to the Company’s common stock in either year. At December 31, 2024 and 2023, net realized losses on sale of the Company’s common stock totaled approximately $15,371 and $10,850, respectively, and net unrealized (depreciation) appreciation of the Company’s common stock totaled approximately $(115,383) and $26,163, respectively.

    Certain fees of administering the Plan are paid to the Trustees by the Plan. For the year ended December 31, 2024, total fees paid to the Trustees were $341,312. Audit fees for the Plan are paid to the independent registered public accounting firm by the Plan. For the year ended December 31, 2024, total fees paid to an independent registered public accounting firm were $42,500. These transactions qualify as exempt party-in-interest transactions. Notes receivable from participants also qualify as exempt party-in-interest transactions.


    7. Plan Termination

    Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of Plan termination, active participants at the time of the termination will remain fully vested in their accounts.


    8. Subsequent Events

    The Plan has evaluated subsequent events from the date the Statement of Net Assets Available for Benefits through June 26, 2025, the date the financial statements were available to be issued. During this period, no material subsequent events were identified.
    8

    ENOVIS 401(k) SAVINGS PLAN PLUS
    EIN: 54-1887631 Plan: 037

    SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)
    DECEMBER 31, 2024
    Identity of Issue, Borrower, Lessor, or Similar PartyDescription of Investment
     Cost(1)
    Current Value
    Enovis Corporation(2)
    Common Stock$481,990 
    ESAB CorporationCommon Stock368,044 
    AB Small Cap Growth Portfolio Class ZMutual Fund4,168,784 
    American Beacon Small Cap Value Fund R6 ClassMutual Fund3,505,242 
    Columbia Dividend Income Fund Institutional 3 ClassMutual Fund4,268,064 
    Fidelity 500 Index FundMutual Fund43,459,639 
    Fidelity International Index FundMutual Fund4,818,377 
    Fidelity Mid Cap Index FundMutual Fund12,709,493 
    Goldman Sachs GQG Partners International Opportunities Fund Institutional SharesMutual Fund6,981,039 
    Janus Henderson Enterprise Fund Class NMutual Fund9,446,660 
    JPMorgan Large Cap Growth Fund Class R6Mutual Fund33,284,134 
    Loomis Sayles Core Plus Bond Fund Class NMutual Fund4,086,438 
    PGIM High Yield Fund- Class R6Mutual Fund2,672,109 
    Vanguard Emerging Markets Stock Index Fund Admiral Shares Mutual Fund2,401,479 
    Vanguard Intermediate-Term Bond Index Fund Admiral SharesMutual Fund4,679,687 
    Vanguard Target Retirement 2020 FundCommon Collective Trust3,537,112 
    Vanguard Target Retirement 2025 FundCommon Collective Trust8,451,318 
    Vanguard Target Retirement 2030 Fund Common Collective Trust28,858,051 
    Vanguard Target Retirement 2035 Fund Common Collective Trust18,855,619 
    Vanguard Target Retirement 2040 Fund Common Collective Trust18,206,122 
    Vanguard Target Retirement 2045 FundCommon Collective Trust25,768,355 
    Vanguard Target Retirement 2050 FundCommon Collective Trust16,377,038 
    Vanguard Target Retirement 2055 Fund Common Collective Trust10,091,418 
    Vanguard Target Retirement 2060 Fund Common Collective Trust7,444,630 
    Vanguard Target Retirement 2065 FundCommon Collective Trust2,052,619 
    Vanguard Target Retirement 2070 FundCommon Collective Trust95,481 
    Vanguard Target Retirement Income FundCommon Collective Trust928,335 
    Morley Stable Value FundCommon Collective Trust11,208,384 
    Total investments per Financial Statements289,205,661 
    Participant loans(2)(3)
    N/A2,789,070 
    $291,994,731 
    __________
    (1) Cost information is not required for participant-directed investments
    (2) A party-in-interest to the plan as defined by ERISA
    (3) Annual interest rates range from 4.25% and 9.5%
    9



    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the Plan) have duly caused this annual report to be signed on its behalf by the undersigned thereunto duly authorized.

    Registrant:     Enovis Corporation
            Enovis 401(k) Savings Plan Plus

    By:    

    /s/ KATRIONA KNAUSJune 26, 2025
    Katriona Knaus
    Vice President, Finance and Treasurer








































    10


    EXHIBIT INDEX

    Exhibit No.Exhibit Description
    23.1
    Consent of Independent Registered Public Accounting Firm
    11
    Get the next $ENOV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ENOV

    DatePrice TargetRatingAnalyst
    10/3/2024$62.00Mkt Outperform
    JMP Securities
    6/13/2024$53.00Neutral
    JP Morgan
    2/13/2024$72.00Overweight
    Stephens
    1/22/2024$75.00Buy
    UBS
    1/3/2024Outperform
    William Blair
    12/15/2023$62.00 → $70.00Buy
    Needham
    10/20/2023$75.00Buy
    ROTH MKM
    6/26/2023$70.00Buy
    Needham
    More analyst ratings

    $ENOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enovis to Participate in Upcoming Investor Conferences

      Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time.Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meetings on Tuesday, June 17th. A link to the live audio webcasts, if available, as well as a replay of these events, will be available on the Company's website u

      6/6/25 4:05:00 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Announces First Quarter 2025 Results

      Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

      5/8/25 6:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis to Host First Quarter 2025 Results Conference Call on May 8th

      Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335

      4/17/25 7:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lalor Angela S was granted 718 shares, increasing direct ownership by 4% to 20,553 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      7/1/25 9:00:05 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SVP, Chief Financial Officer Berry Phillip Benjamin (Ben) covered exercise/tax liability with 1,013 shares, decreasing direct ownership by 0.88% to 114,229 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      6/3/25 9:00:06 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Director Kelly Liam was granted 6,598 shares, increasing direct ownership by 51% to 19,604 units (SEC Form 4)

      4 - Enovis CORP (0001420800) (Issuer)

      5/23/25 9:00:06 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    SEC Filings

    See more
    • SEC Form 11-K filed by Enovis Corporation

      11-K - Enovis CORP (0001420800) (Filer)

      6/26/25 4:45:47 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SD filed by Enovis Corporation

      SD - Enovis CORP (0001420800) (Filer)

      5/30/25 4:05:37 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form 8-K filed by Enovis Corporation

      8-K - Enovis CORP (0001420800) (Filer)

      5/21/25 4:07:27 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Leadership Updates

    Live Leadership Updates

    See more
    • Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

      Damien McDonald appointed CEO, effective as of May 12, 2025Company reiterates guidance for first quarter revenues and aEBITDA WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "The Company") (NYSE:ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at th

      4/2/25 6:30:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Maplebear Set to Join S&P MidCap 400; Enovis to Join S&P SmallCap 600

      NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Maplebear Inc. (NASD: CART) will replace Enovis Corp. (NYSE:ENOV) in the S&P MidCap 400, and Enovis will replace Arch Resources Inc. (NYSE:ARCH) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 14. S&P SmallCap 600 constituent CONSOL Energy Inc. (NYSE:CEIX) is acquiring Arch Resources in a deal expected to be completed soon, pending final closing conditions. Following completion of the merger, CONSOL Energy will be renamed Core Natural Resources Inc., and its ticker will change to CNR. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index

      1/7/25 6:19:00 PM ET
      $ARCH
      $CART
      $CEIX
      $ENOV
      Coal Mining
      Energy
      Business Services
      Consumer Discretionary
    • Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

      WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Enovis™ (NYSE:ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company's U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis' Reconstructive (Recon) Business Group. Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in le

      9/9/24 3:50:00 PM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Financials

    Live finance-specific insights

    See more
    • Enovis Announces First Quarter 2025 Results

      Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. First Quarter 2025 Financial Results Enovis' first-quarte

      5/8/25 6:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis to Host First Quarter 2025 Results Conference Call on May 8th

      Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE:ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com. Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 335

      4/17/25 7:00:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Enovis Announces Fourth Quarter and Full Year 2024 Results

      Continued commercial momentum with fourth-quarter sales growth of 23% on a reported basis and strong adjusted EBITDA margin expansion Fourth-quarter Reconstructive sales grew 59% year-over-year on a reported basis and 10% on a Comparable Sales basis Exceeded year one commercial and integration plans for Lima Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation ("Enovis" or "the Company") (NYSE:ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. F

      2/26/25 6:01:00 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JMP Securities initiated coverage on Enovis Corporation with a new price target

      JMP Securities initiated coverage of Enovis Corporation with a rating of Mkt Outperform and set a new price target of $62.00

      10/3/24 7:29:21 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • JP Morgan initiated coverage on Enovis Corporation with a new price target

      JP Morgan initiated coverage of Enovis Corporation with a rating of Neutral and set a new price target of $53.00

      6/13/24 7:06:52 AM ET
      $ENOV
      Industrial Specialties
      Health Care
    • Stephens initiated coverage on Enovis Corporation with a new price target

      Stephens initiated coverage of Enovis Corporation with a rating of Overweight and set a new price target of $72.00

      2/13/24 6:34:49 AM ET
      $ENOV
      Industrial Specialties
      Health Care

    $ENOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enovis Corporation

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      11/14/24 1:28:31 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      4/5/24 12:21:51 PM ET
      $ENOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed by Enovis Corporation (Amendment)

      SC 13G/A - Enovis CORP (0001420800) (Subject)

      2/14/24 10:04:36 AM ET
      $ENOV
      Industrial Specialties
      Health Care